U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018596) titled 'NS-PFA Catheter Ablation of Paroxysmal and Persistent Atrial Fibrillation With the Pulse Biosciences CellFX System' on June 05.
Brief Summary: The objective of this study is to demonstrate the safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA) Catheter Endocardial Ablation System in treating recurrent, drug-resistant, symptomatic paroxysmal and persistent atrial fibrillation (AF).
Study Start Date: Aug. 25
Study Type: INTERVENTIONAL
Condition:
Atrial Fibrillation Paroxysmal
Cardiac Ablation
Cardiac Arrhythmia
Atrial Fibrillation, Persistent
Intervention:
DEVICE: CellFX nsPFA Endocardial Ablation C...